Skip to content
Home/GPs/Verto
Verto

Verto

Paris, France·Founded 2016··vertogrowth.com

Paris-based independent growth and buyout PE firm founded 2016 by Antoine Dary, specializing in B2B Software and HealthTech investments across France, Benelux and Switzerland with EUR 15-60M tickets. Manages around EUR 470M across Verto Growth I (2020 EUR 140M Harvesting) and Verto Growth II (2025 EUR 330M final close July 2025 hard cap, Investing); notable exits BioBank August 2024 to IK Partners and Presto Engineering 2024 to Dentressangle Capital.

AUM
€470M
Funds
2
vintages 2020–2025
Portfolio
11
Exits
3
SectorsSoftwareHealthcare

Key facts

HQParis, France
Founded2016

Recent exits

BioBank
Healthcare · 2024 · 9yr hold
Presto Engineering
Industrials · 2024 · 6yr hold
OMP Transport
TMT · 2023 · 4yr hold

Coverage notes

2 funds tracked, 14 portfolio companies (11 active · 3 realized). Verified weekly from public filings and deal announcements.

Funds & portfolio

Every fund Verto has raised, with its portfolio companies. Hand-checked from public filings.

2 funds
Verto Growth IIGrowth
2025 · 1yr€330M3 active

Unrealized

3 held
IskeraActive
TMTFrance· Entry 2025
TMTFrance· Entry 2022
MyTowerActive
TMTFrance· Entry 2025
Verto Growth IGrowth
2020 · 6yr€140M8 active · 3 realized

Unrealized

8 held
CBAActive
HealthTechFrance· Entry 2019
CHR GroupActive
TMTFrance· Entry 2020
Business ServicesFrance· Entry 2021
TMTFrance· Entry 2021
ElapActive
HealthcareFrance· Entry 2022
TMTFrance· Entry 2020
LessoniaActive
IndustrialsFrance· Entry 2018
TMTFrance· Entry 2021

Realized

3 exits
BioBankExited 2024
HealthcareFrance· Entry 2015
Secondaryto
OMP TransportExited 2023
TMTFrance· Entry 2019
Secondaryto
IndustrialsFrance· Entry 2018
Secondaryto
Track Verto

Saved GPs appear in your watchlist, one click from your workspace.

About Verto

Verto is a Paris-based independent growth and buyout private equity firm with €470 million of assets under management, founded in 2016 by Antoine Dary. The firm specialises in B2B Software and HealthTech investments across France, Benelux and Switzerland, deploying capital across Verto Growth I and II vintage funds with equity tickets ranging from €15 million to €60 million per transaction.

Investment thesis

Verto targets European B2B Software and HealthTech companies at growth equity and selective buyout stages, with sector focus on enterprise software, vertical SaaS, healthcare technology and selective fintech verticals. The pan-European mandate covering France, Benelux and Switzerland provides distinctive deal flow across French-speaking and DACH-adjacent European tech markets. Equity ticket sizes enable Verto to participate in scaling rounds for profitable European tech companies.

Recent activity

Recent realised exits include BioBank (healthcare, 2024) and Presto Engineering (industrials, 2024), reflecting active distribution across the B2B technology portfolio. The platform tracks 2 funds and 11 active portfolio companies across the multi-vintage European tech programme. Detailed buyer names and multiple data available on Pro at €29/month.

Last updated June 2026 · Sourced from public filings